文献速递乳腺癌放疗

SENOMAC随机试验:肩关节放疗剂量与乳腺癌患者手臂症状的相关性

Association between shoulder joint radiation dose and arm morbidity in the randomized breast cancer trial SENOMAC.
PubMed 文献 · Radiother Oncol · 2026-02-21

基于SENOMAC随机试验中868例瑞典乳腺癌患者放疗计划,分析肩关节剂量与手臂症状的关系。剂量可评估386例腋窝淋巴结清扫和421例前哨淋巴结活检患者。前哨淋巴结活检组中,较高近最大剂量(D0.5cc)与术后三年手臂症状评分显著更差相关,尤其在保乳手术患者中;腋窝淋巴结清扫组无此关联,未找到剂量阈值。

要点

  • 前哨淋巴结活检组肩关节D0.5cc较高与术后3年手臂症状更差显著相关。
  • 该关联在保乳手术患者中尤为明显,腋窝淋巴结清扫组未见关联。
  • 未识别出肩关节症状的剂量阈值,需延长随访进一步验证。

核心结论

  • 肩关节最大放疗剂量与后续手臂/肩部副作用可能存在关联,尤其在前哨淋巴结活检且保乳手术的患者中。

研究设计与样本

  • 基于SENOMAC随机试验数据,收集868例瑞典患者的放疗计划,自动勾画肱骨头并外放1 cm代表肩关节,使用Lymph-ICF问卷评估手臂症状。

主要发现

  • 剂量可评估386例腋窝淋巴结清扫和421例前哨淋巴结活检患者,两组肩关节剂量分布相似。
  • 前哨淋巴结活检组中,较高近最大剂量(D0.5cc)与术后三年手臂症状评分显著更差相关,尤其在保乳手术患者中。
  • 腋窝淋巴结清扫组未发现剂量与手臂症状的关联。
  • 未识别出发生手臂/肩部相关副作用的剂量阈值。

关键数值与推荐

  • 前哨淋巴结活检组中较高D0.5cc与术后三年手臂症状评分显著更差相关,但未报告具体剂量数值或阈值。

临床怎么用

  • 在乳腺癌前哨淋巴结活检后放疗中,尤其保乳手术患者,应关注肩关节近最大剂量,但目前尚无公认的剂量-体积约束。

局限性

  • 未识别出剂量阈值,需SENOMAC试验延长随访进一步分析手臂症状发生率与放疗剂量的时间关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postoperative lymph node irradiation can affect shoulder morbidity in breast cancer patients, yet widely accepted dose-volume constraints for the shoulder joint are lacking. The SENOMAC trial randomized patients with breast cancer and 1-2 sentinel lymph node (SLN) macrometastases to axillary lymph node dissection (ALND) or SLN biopsy only. We aimed to analyze the association between the radiation dose to the shoulder joint and patient-reported arm morbidity one and three years after surgery using SENOMAC data. METHODS: Radiotherapy plans from 868 Swedish SENOMAC patients randomized 2015-2019 were collected. The humeral head was auto-segmented, and a 1 cm margin added to represent the shoulder joint. Arm morbidity was assessed using the Lymph-ICF questionnaire, focusing on questions regarding physical arm function and shoulder-related mobility tasks. RESULTS: The radiation dose was evaluable for 386 patients receiving ALND and 421 receiving SLN biopsy. The dose distribution to the shoulder joint was similar in both study groups. In the SLN group, a higher near-maximum dose (D0.5cc) was associated with significantly worse arm morbidity scores three years after surgery, particularly among patients treated with breast-conserving surgery. No association was found in the ALND group. No dose thresholds for development of arm/shoulder related side effects could be identified. CONCLUSION: Our results indicate a possible association between maximum radiation dose to the shoulder joint and subsequent side effects. Extended follow-up within SENOMAC will provide further insights into the incidence of arm morbidity in relation to radiotherapy dose over time.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Alkner S, Appelgren M, Szulkin R, et al. Association between shoulder joint radiation dose and arm morbidity in the randomized breast cancer trial SENOMAC. Radiother Oncol. 2026. PMID: 41730479. doi:10.1016/j.radonc.2026.111454

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。